Materialise NV is a prominent provider of additive manufacturing and medical software tools, as well as 3D printing services, headquartered in Leuven, Belgium. Founded in 1990 by Wilfried Vancraen and Hilde Ingelaere, the company has evolved from a rapid prototyping service bureau into a key player in the 3D printing industry. Materialise's offerings include proprietary software solutions that enhance the operation of 3D printers (Materialise Software), medical software for image-based analysis and patient-specific device design (Materialise Medical), and comprehensive 3D printing services for various sectors (Materialise Manufacturing). Materialise serves a diverse range of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, employing approximately 2,556 individuals globally. In 2025, the company reported revenues of $302.7 million and is publicly traded on both the Nasdaq and Euronext Brussels under the ticker symbol MTLS. In November 2025, it launched an additional listing on Euronext Brussels, complementing its Nasdaq presence. The headquarters in Leuven is notable for housing one of the largest 3D printing service centers worldwide, powered entirely by green energy. Materialise collaborates with several significant partners in the medical field, including Zimmer Biomet Holdings, DePuy Synthes Companies, Medtronic, and Abbott Laboratories. As of August 27, 2026, Materialise's stock price is $6.67 USD, with a market capitalization of approximately $393.98 million.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
MATERIALISE's offering is currently approved on OTHER. MATERIALISE is headquartered in Belgium. It is classified under Tech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with MATERIALISE.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/materialise" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="MATERIALISE — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/materialise?theme=light as the src instead.
https://www.discoveripo.com/ipo/materialise/opengraph-image
MATERIALISE IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/materialise?utm_source=embed&utm_medium=text&utm_campaign=materialise
Get emailed when MATERIALISE's terms, price, or expected date change — no weekly noise, just this company.
MATERIALISE is listing on OTHER.
Materialise NV is a prominent provider of additive manufacturing and medical software tools, as well as 3D printing services, headquartered in Leuven, Belgium. Founded in 1990 by Wilfried Vancraen and Hilde Ingelaere, the company has evolved from a rapid prototyping service bureau into a key player in the 3D printing industry. Materialise's offerings include proprietary software solutions that enhance the operation of 3D printers (Materialise Software), medical software for image-based analysis and patient-specific device design (Materialise Medical), and comprehensive 3D printing services for various sectors (Materialise Manufacturing). Materialise serves a diverse range of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, employing approximately 2,556 individuals globally. In 2025, the company reported revenues of $302.7 million and is publicly traded on both the Nasdaq and Euronext Brussels under the ticker symbol MTLS. In November 2025, it launched an additional listing on Euronext Brussels, complementing its Nasdaq presence. The headquarters in Leuven is notable for housing one of the largest 3D printing service centers worldwide, powered entirely by green energy. Materialise collaborates with several significant partners in the medical field, including Zimmer Biomet Holdings, DePuy Synthes Companies, Medtronic, and Abbott Laboratories. As of August 27, 2026, Materialise's stock price is $6.67 USD, with a market capitalization of approximately $393.98 million.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy